Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Veru Inc VERU

Consumer Defensive Household & Personal Products
Veru Inc. is a late clinical-stage biopharmaceutical company focused on developing novel medicines for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its drug development program includes two late-stage novel small molecules, enobosarm and sabizabulin. Enobosarm, a selective androgen receptor modulator, is being developed in two different programs... see more

Recent & Breaking News (NDAQ:VERU)

Veru Extends Agreement with Roman for Veru's Premature Ejaculation Treatment Product

GlobeNewswire August 18, 2020

Veru Reports Higher Net Revenues for Fiscal 2020 Third Quarter

GlobeNewswire August 13, 2020

VERU-111 Suppresses Key Cytokines Responsible for Severe Acute Respiratory Distress Syndrome in COVID-19

GlobeNewswire August 4, 2020

Veru to Report Fiscal 2020 Third-Quarter Financial Results, Host Conference Call on August 13th

GlobeNewswire July 30, 2020

Veru Announces ESMO Congress 2020 Acceptance of VERU-111, a Novel Oral Tubulin Targeting Agent, Phase 1b/2 Study in Metastatic Prostate Cancer as an Oral Presentation

GlobeNewswire July 27, 2020

Veru Receives Positive Input from FDA on Phase 3 Pivotal Trial to Evaluate VERU-111 in Metastatic Castration Resistant Prostate Cancer

GlobeNewswire July 23, 2020

Veru Inc. Added to the Russell 2000 and 3000 Indices

GlobeNewswire June 29, 2020

Veru Enrolls First Patient in Phase 2 Clinical Trial of Novel Drug, VERU-111, to Combat COVID-19

GlobeNewswire June 19, 2020

Veru to Present at Jefferies Virtual Healthcare Conference on June 2nd

GlobeNewswire May 26, 2020

Veru Reports Strong Fiscal 2020 Second Quarter Results as Net Revenues Increase 43%, Gross Profit Up 61%

GlobeNewswire May 13, 2020

Veru Secures FDA Agreement to Initiate Phase 2 Study of VERU-111, Novel Microtubule Depolymerization Drug to Combat COVID-19

GlobeNewswire May 12, 2020

Veru to Report Fiscal 2020 Second-Quarter Financial Results, Host Conference Call on May 13th

GlobeNewswire May 6, 2020

Veru Reports Positive Clinical Results from VERU-111 Phase 1b/2 Trial in Men with Metastatic Castration-Resistant Prostate Cancer, Advancing to Pivotal Phase 3 Clinical Program

GlobeNewswire May 5, 2020

Veru Initiates Phase 2 Clinical Trial of VERU-111, First-in-Class, Oral, Advanced Prostate Cancer Drug

GlobeNewswire February 26, 2020

Veru Continues Strong Positive Sales Momentum in Fiscal 2020 First Quarter; Net Revenues Increase 66%, Gross Profit Up 57%

GlobeNewswire February 12, 2020

Veru to Report Fiscal 2020 First-Quarter Financial Results, Host Conference Call on February 12th

GlobeNewswire February 5, 2020

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Veru Inc. - VERU

ACCESSWIRE IA January 30, 2020

Veru Announces Acceptance of Two Abstracts for Presentation at the Genitourinary Cancer Symposium in February 2020

GlobeNewswire January 21, 2020

Veru Announces Positive Top-Line Interim Data from Phase 2 Clinical Trial of Zuclomiphene to Treat Hot Flashes in Men with Prostate Cancer on Androgen Deprivation Therapy

GlobeNewswire January 13, 2020

Veru Reports Fiscal 2019 Full-Year Net Revenues Doubled, Gross Profit Up 147%

GlobeNewswire December 12, 2019